Plain-English translation of NCT07330037 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination treatment for people with advanced lung cancer who have already had surgery. The treatment uses your own immune cells (called tumor-infiltrating lymphocytes, or TILs) along with a medication called . This approach is designed for patients whose cancer didn't completely disappear after initial chemotherapy and immunotherapy treatment before surgery.
Some patients with lung cancer don't fully respond to standard chemotherapy and immunotherapy before surgery, meaning cancer cells may still remain. Researchers are testing whether giving patients their own specially processed immune cells along with this medication after surgery might help their immune system fight any remaining cancer and reduce the chance of the disease returning.
You likely qualify if…
You likely don't qualify if…
You will receive treatment over several months. Your own immune cells will be collected, processed in the laboratory, and then infused back into you four separate times. Between each cell infusion, you will receive the medication intravenously. The entire treatment course involves 8 cycles of medication spread over about 6 months. You will have regular clinic visits and blood tests to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China